Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil
...on efficacy outcome parameters in metastatic colorectal cancer
Recent publication
Trifluridine/tipiracil is used to treat metastatic colorectal cancer. The effectiveness of the combination drug appears to be reduced in the presence of the KRAS G12 gene mutation, which affects the RAS protein. The researchers looked at the survival of 123 patients from five cancer centres who received trifluridine/tipiracil in combination with bevacizumab, an antibody that targets a specific growth factor. The real-world data set allowed the survival and efficacy of this combination therapy to be compared in patients with and without the KRAS G12 mutation. The University Hospital St. Pölten was involved in the study with Dr Hossein Taghizadeh, MSc and Dr Therese Lentner, BSc, both from the Division of Internal Medicine 1. The results are freely available in ESMO open.
Doleschal B, Taghizadeh H, Lentner T, Riedl JM, Granitzer J, Morariu D et al. Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer. ESMO Open. 2023 Nov 16;8(6):102064. Epub 2023 Nov 16. doi: 10.1016/j.esmoop.2023.102064
PD Dr. Hossein Taghizadeh MSc PhD
Division of Internal Medicine 1 (University Hospital St. Pölten)
Dr. Theresa Lentner BSc
Division of Internal Medicine 1 (University Hospital St. Pölten)
